<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Santen Pharmaceutical Co., Ltd. — News on 6ix</title>
    <link>https://6ix.com/company/santen-pharmaceutical-co-ltd</link>
    <description>Latest news and press releases for Santen Pharmaceutical Co., Ltd. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 08 Jan 2026 12:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/santen-pharmaceutical-co-ltd" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d62180beedb30cb6fc2c29.webp</url>
      <title>Santen Pharmaceutical Co., Ltd.</title>
      <link>https://6ix.com/company/santen-pharmaceutical-co-ltd</link>
    </image>
    <item>
      <title>RVL Pharmaceuticals Announces Santen Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ® Mini Ophthalmic Solution 0.1%</title>
      <link>https://6ix.com/company/santen-pharmaceutical-co-ltd/news/rvl-pharmaceuticals-announces-santen-obtains-manufacturing-and-marketing-approval-in-japan-for-upneeqr-mini-ophthalmic-solution-01percent</link>
      <guid isPermaLink="true">https://6ix.com/company/santen-pharmaceutical-co-ltd/news/rvl-pharmaceuticals-announces-santen-obtains-manufacturing-and-marketing-approval-in-japan-for-upneeqr-mini-ophthalmic-solution-01percent</guid>
      <pubDate>Thu, 08 Jan 2026 12:00:00 GMT</pubDate>
      <description>RVL Pharmaceuticals, Inc. and its affiliates (together, &quot;RVL&quot;) announces Santen Pharmaceutical Co., Ltd. (&quot;Santen&quot;), a leading ophthalmology company has obtained the manufacturing and marketing approval in Japan for UPNEEQ® Mini Ophthalmic Solution 0.1% (generic name: oxymetazoline hydrochloride; development code: STN1013800; hereinafter the product), a treatment for acquired blepharoptosis (low-lying eyelids).</description>
    </item>
    <item>
      <title>RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries</title>
      <link>https://6ix.com/company/santen-pharmaceutical-co-ltd/news/remegen-and-santen-enter-into-exclusive-licensing-agreement-for-ophthalmic-innovative-drug-rc28-e-in-greater-china-and-asian-countries</link>
      <guid isPermaLink="true">https://6ix.com/company/santen-pharmaceutical-co-ltd/news/remegen-and-santen-enter-into-exclusive-licensing-agreement-for-ophthalmic-innovative-drug-rc28-e-in-greater-china-and-asian-countries</guid>
      <pubDate>Tue, 19 Aug 2025 00:00:00 GMT</pubDate>
      <description>RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, &quot;RemeGen&quot;), a leading Chinese biopharmaceutical company, announced today that it has entered into an agreement with Santen Pharmaceutical (China) Co., Ltd. (&quot;Santen China&quot;), a wholly-owned subsidiary of Santen Pharmaceutical Co., Ltd. (&quot;Santen&quot;). Under the agreement, Santen China has obtained exclusive rights to develop, manufacture, and commercialize RC28-E in Greater China (including Mainland China, Hong Kong, Macau, and Taiwan) as well as in</description>
    </item>
  </channel>
</rss>